Survivin and XIAP are members of inhibitors of apoptosis (IAPs) family. They are upregulated in various malignancies. Inactivation of these molecules has resulted in chemosensitization. The purpose of this study was to determine whether inhibition of survivin, XIAP, or both enhances radiotherapy in a lung cancer model. Transient transfection of H460 cells with antisense oligonucleotides (ASOs) against either molecule has specifically reduced their expression, by Western analysis. Results from 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide and clonogenic assays suggest that inhibition of survivin or XIAP greatly decreased cell survival following irradiation. A significantly increased number of apoptotic cells were detected when H460 cells were treated with either antisurvivin, anti-XIAP or both ASOs (P ¼ 0.03, 0.0003 and 0.01, respectively) plus irradiation. H460 xenografts that were treated with ASOs plus radiotherapy demonstrated growth delay beyond 15 days. Growth delay in the groups of combined treatment was greater than that in other groups. However, treatment with ASOs alone did not affect tumor growth delay in mice, but decreased the survival of H460 cells in culture. Antisense treatment did not cause any mortality or weight loss during the 32 days of study. These data suggest that inhibition of survivin or XIAP radiosensitizes H460 lung cancer cells by upregulating apoptosis and downregulating cell survival. Combination of radiotherapy and inhibition of survivin and XIAP through the antisense approach results in improved tumor control by radiotherapy in a mouse model of lung cancer.
Introduction
Inhibitor of apoptosis (IAP) protein is a family of proteins that regulate cell death (Salvesen and Duckett, 2002) . X-linked IAP and survivin are two important members of the mammalian IAP family. Both were shown to inhibit caspases and block the apoptotic pathway (Salvesen and Duckett, 2002) . In addition, survivin plays an important role in mitosis by interacting with other chromosomal passenger proteins such as INCEPT and AURORA B (Adams et al., 2001 ). An important feature of these molecules is that there are upregulated in various malignancies (Bao et al., 2002) . Clinically, high levels of XIAP or survivin have been associated with decreased overall survival, increased recurrence and resistance to radiotherapy (Holcik et al., 2000; Rodel et al., 2003) . Several reports demonstrated an association between high levels of survivin and poor survival in patients with resected non-small-cell lung cancer (Monzo et al., 1999; Ikehara et al., 2002) . However, similar association has not been consistently found for XIAP (Ferreira et al., 2001; Hofmann et al., 2002) . Inhibition of survivin or XIAP via antisense oligonucleotides (ASOs) has enhanced sensitivity of lung cancer xenografts to chemotherapy. (Olie et al., 2000; Hu et al., 2003) . Inhibition of survivin via a ribozyme has resulted in radiosensitization of melanoma xenografts (Pennati et al., 2003) . XIAP and survivin are also involved in tumor angiogenesis (Papapetropoulos et al., 2000; Harfouche et al., 2002) . Their levels in endothelial cells are induced by VEGF (Tran et al., 1999 (Tran et al., , 2002 O'Connor et al., 2000; Mesri et al., 2001) . Inhibition of survivin by its T34A dominant-negative mutant significantly reduced tumor-associated angiogenesis (Blanc-Brude et al., 2003) . Therefore, both XIAP and survivin are logical targets for controlling tumor growth and angiogenesis (Holick et al., 2001; Altieri, 2003) . Here, we examined the effects of radiosensitization in the H460 lung cancer model via inhibiting survivin and XIAP using antisense approach. We found that ASOs against survivin or XIAP reduce survival of H460 cells in culture and increase tumor growth delay of H460 xenografts when combined with radiation.
Results
ASOs result in specific attenuation of survivin or XIAP ASOs against survivin or XIAP have been used to inhibit the expression of these molecules in lung cancer cell lines (Olie et al., 2000; Hu et al., 2003) . In order to determine whether there is reduction of survivin or XIAP following transfection of these ASO (ASOs), anti-survivin, anti-XIAP or a missense (MS) control oligo were transiently transfected into H460 cells using Lipofectin. Protein levels of survivin or XIAP were determined by Western immunoblots 48 h following transfection. As shown in Figure 1 , the ASO against survivin attenuated survivin expression and the ASO against XIAP reduced the level of XIAP, as compared to b-actin, which was not affected by either ASO.
Inhibition of survivin or XIAP sensitizes H460 cells to radiation by increasing apoptosis and decreasing cell viability
Inhibition of survivin or XIAP sensitizes lung cancer cells to chemotherapeutic agents (Olie et al., 2000; Hu et al., 2003) . To determine whether inhibition of survivin or XIAP sensitizes H460 cells to radiotherapy, the ASOs against survivin, XIAP or both were transfected into H460 cells. This was followed by either 0 or 2 Gy. After 48 h, the percentage of apoptotic cells was determined by flow-cytometry analysis of 7-aminoactinomycin D (7AAD)-stained cells. As shown in Figure 2a , radiation alone increased apoptotic cells from 5 to 10%, while either anti-survivin or anti-XIAP oligo alone increased apoptotic population to 15%. In comparison, irradiation of cells that were transfected with either antisurvivin or anti-XIAP oligo significantly increased the apoptotic population to almost 30% (P ¼ 0.035 and 0.0003, respectively). To test the potential synergism between the two ASOs, they were equally mixed (150 nM þ 150 nM) to have the same final concentration of 300 nM as that of single ASO and transfected into H460 cells. As shown in Figure 2b , no further increase in apoptosis was detected when the anti-survivin and anti-XIAP oligos were combined.
To determine the cell viability following the various treatments described, 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay was performed at 48 h after irradiation. As shown in Figure 2b , radiation alone decreased the MTT proliferative activity from 95 to 85%, while either antisurvivin or anti-XIAP oligo alone decreased the MTT activity to 45-50% (P ¼ 0.00015 and 0.00078, respectively). However, irradiation of cells transfected with either anti-survivin or anti-XIAP oligo decreased the viable cells to 30-35%. Interestingly, only 20% viable cells were present following simultaneous inhibition of survivin and XIAP by both ASOs. Irradiation of cells transfected with both ASOs resulted in the maximal reduction of MTT activity, that is, only less than 10% of viable activity was detected.
To confirm the results from the MTT assay, clonogenic assays were performed. H460 cells were transfected by the control ASO (300 nM), anti-survivin (300 nM), anti-XIAP (300 nM), or anti-survivin (150 nM) plus anti-XIAP (150 nM). A nontransfected control was used to show the toxicity of transfection. The transfected cells or nontransfected control were treated with 0-5 Gy. After 2 weeks, colonies were stained and the scored colonies are graphed in Figure 3 . As shown, cells transfected with either anti-survivin or anti-XIAP had less surviving colonies as compared to the cells transfected by the control oligo (MS). Cells transfected with both ASOs had the lowest survival curve following irradiation.
Inhibition of survivin and XIAP enhanced radiation-induced tumor regression
To determine whether the ASOs against survivin or XIAP enhance radiation-induced tumor volume regression, H460 xenograft model was established and tumor volumes were measured by use of calipers, as described previously (Geng et al., 2001; Edwards et al., 2002) . H460 tumor-bearing mice were treated with 2 Gy daily for 5 days. ASO was given 2 days before the first radiotherapy and daily for 7 days at a dose of 15 mg/kg by intraperitoneal injections. A nontreatment control was used to determine the nonspecific effects of oligonucleotides. As shown in Figure 4a , the treatment of ASOs alone (15 mg/kg) exhibited no tumor growth delay as no difference was detected between the sequence-specific ASOs and the control ASO. However, administration of anti-survivin, anti-XIAP or both (7.5 mg/kg for each ASO), which was followed by radiotherapy, caused significant reduction in tumor volumes at various time points. Tumor growth delay was the greatest (more than fourteen days) in the group treated with two ASOs plus radiotherapy. To determine the systemic toxicities from the various treatments, body weight was recorded among all experimental groups as a surrogate. As shown in Figure 4b , only the groups treated with radiotherapy had mild loss of body weight (o5% of the pretreatment value).
Discussion
In the present study, inhibition of survivin and XIAP using ASOs has significantly enhanced the efficacy of radiotherapy in reducing survival and increasing apoptosis of lung cancer cells. The combination therapy resulted in significant growth delay of H460 xenografts without increasing severe toxicities. Inhibition of both targets in antiapoptotic pathway caused the maximal radiosensitization. 
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Anti-S150nM+Anti-X 150nM Both survivin and XIAP are major players in inhibiting apoptotic signals from the host environment. Their levels are upregulated in malignancies so that the cancer cells are resistant to cytotoxic effects of chemotherapy or radiotherapy (Rodel et al., 2003; Lu et al., 2004) . We and others have shown that high level of survivin leads to radiation resistance. Similarly, elevated survivin or XIAP contributed to resistance to chemotherapy (Holcik et al., 2000; Rodel et al., 2003) . A logical approach is to inhibit these antiapoptotic targets in order to sensitize cancer cells to cytotoxic therapies. One of the targeted therapeutics is ASO-based therapy. ASO has been very effective in specifically inhibiting the translation of its target, by interacting with the matching mRNA. ASO has recapitulated biological phenotypes in cell culture as a result of inhibiting the expression of its target. It has demonstrated significant antitumor, or chemosensitizing effects in several studies using animal models (Jansen and Zangemeister-Wittke, 2002) . Specifically, the ASO against survivin sensitized A549 lung cancer cells to Etoposide, while the ASO against XIAP sensitized H460 lung cancer cells to various chemotherapeutic agents such as Doxorubicin, Taxol, and Etoposide (Olie et al., 2000; Hu et al., 2003) . These studies have significant implications in future management of non-small-cell lung cancer, since a preliminary report at 2003 ASCO showed that the ASO against bcl-2 enhanced the chemotherapeutic effects among patients with melanoma. In the present study, ASO against either survivin or XIAP was found to sensitize radiotherapy in a lung cancer model. Concurrent targeting of both survivin and XIAP resulted in maximal sensitization. Intriguingly, the mice treated with the ASOs only did not show any tumor growth delay, whereas each of these ASOs induced apoptosis and decreased cell survival in the cell culture model. It is possible that the in vivo delivery of these ASOs is rather inefficient so that only radiosensitizing effect is manifested.
Both survivin and XIAP share the homology of baculovirus IAP repeat (BIR) domain, which is involved in binding various caspases, the downstream effectors of apoptosis (Salvesen and Duckett, 2002) . Survivin was shown to bind and inhibit caspase 9, while XIAP is able to bind and inhibit caspases 3, 7, and 9 (Salvesen and Duckett, 2002). Therefore, XIAP appears to possess a stronger antiapoptotic effect. Therefore, inhibition of XIAP may result in greater degree of apoptosis. When both anti-survivin and anti-XIAP oligos were combined, we did not detect any further increase of apoptosis by the staining of 7AAD. But the combination of both ASOs resulted in further reduction of cell survival by the MTT and clonogenic assays. This was also confirmed by the xenograft study. Alternative mechanisms of cell death occurred following the administration of double ASOs may explain this difference.
Inhibition of survivin by deletion results in a predominant effect on mitosis, a catastrophic defect of microtubule assembly, with absence of mitotic spindles, disorganized tubulin aggregates, and multinucleation, in the survivin knockout mice (Uren et al., 2000) . Colocalization of survivin with Aurora-B and the inner centromere protein (INCENP) suggests that these proteins interact throughout mitosis and are essential for chromosome condensation and segregation, as well as the completion of cytokinesis (Adams et al., 2001; Kallio et al., 2001) . Since survivin has a dual function in completing mitosis, cells may undergo mitotic cell death following inhibition of survivin. Synergistic effect of targeting mitosis (anti-survivin) and apoptosis (anti-XIAP) may arise from hitting two distinctly separate pathways of cell survival. Furthermore, our preliminary data (not shown) suggest that double ASOs had synergistic induction of cell senescence. Both senescence and mitotic cell death reduce cell survival, and are not detected by the assays for apoptosis. This may explain the difference between our results from the assay for apoptosis and our results of cell survival, which are affected by all mechanisms of cell death. Targeting several cell death mechanisms is our rationale of simultaneous inhibition of survivin and XIAP. Our data suggest that inhibition of survivin and XIAP using a mixture of two ASOs led to the maximal radiosensitization.
Survivin has been shown to be essential for tumor angiogenesis. Inhibition of survivin by its T34A mutant increased apoptosis of HUVEC cells and disrupted three-dimensional capillary networks (Blanc-Brude et al., 2003) . Our preliminary result (not shown) suggests that inhibition of survivin or XIAP compromised the ability of HUVEC to form vessels in vitro. Therefore, the combination approach we tested may in fact be antiangiogenic although additional data are needed to support this conclusion.
In summary, our data suggest that the combination of anti-IAPs and irradiation resulted in significantly increased cytotoxicity in lung cancer. Other smallmolecule inhibitors to these targets may be used to confirm our findings (Schimmer et al., 2004) . Further clinical studies are needed to validate IAPs as targets for improving the thoracic chemoradiation therapy in managing unresectable NSCLC.
Materials and methods
Cell culture
H460 lung carcinoma cells were obtained from American Type Culture Collection (Rockville, MD, USA) and maintained in DMEM medium with 10% fetal calf serum and 1% penicillin/ streptomycin. Irradiation (3 Gy) was given by use of a Cobalt-60 radioactive source.
Western immunoblots
Cells were transfected with various ASOs. After 48 h, they were counted and then washed with ice-cold PBS twice before the addition of lysis buffer (20 nM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 2.5 mM sodium NaPPi, 1mM phenylmethylsulfonyl fluoride, and leupeptin). Protein concentration was quantified by the Bio-Rad method. Equal amounts of protein were loaded into each well and separated by 14% SDS-PAGE gel, followed by transfer onto nitrocellulose membranes. Membranes were blocked by use of 10% nonfat dry milk in PBS for 2 h at room temperature. The blots were then incubated with the rabbit-antihuman survivin (R&D systems) and anti-human XIAP (Cell Signal) antibodies overnight at 41C. Donkey antirabbit IgG secondary antibody (1 : 1000; Amersham) was incubated for 1 h at room temperature. Immunoblots were developed by using the enhanced chemiluminescence (ECL) detection system (Amersham) according to the manufacturer's protocol and autoradiography.
Measurement of apoptosis
7AAD (Molecular Probes, Eugene, OR, USA) is a fluorescent DNA-binding stain usually used as a single agent to detect apoptotic cells by flow cytometry. Percent apoptosis was measured by flow cytometric analyses of 7-AAD-stained cells. Cells (4 Â 10 5 ) were plated into 25-cm 2 flasks. After 24 h of 371C incubation, cells were subject to various treatments (transfection or irradiation). At the time of analysis, cells were trypsinized (keeping all floating cells) and counted for each sample. A quantity of 1 Â 10 6 cells was centrifuged and resuspended in the 7AAD-staining buffer. After 15 min incubation at room temperature, cells were washed, fixed by 1% paraformaldehyde, and analysed by FACScan.
ASOs, transfection
ASOs were synthesized (Qiagen, Inc) using the following sequences: the survivin ASOs: 5 0 -TGTGC-TATTCTGT-GAATT-3 0 ; the mismatch control oligo: 5 0 -TAAGC-TGTTCTATGTGTT-3 0 . The underlined nucleotides are 2 0 -O-methoxyethyl modified. The sequence for the antisense against XIAP (G4 AS) was described in Hu et al. (2003) and synthesized by Trilink Biotech. Subconflunet H460 cells were transfected with either oligo using a mixture of Lipofectin (Gibco, MD, USA) and oligos in Opti-MEM media (Gibco) at a ratio of 3 ul Lipofectin/ml media per 100 nM oligo. After being incubated for 4 h, cells were replaced by the regular complete media.
MTT assay
Briefly, cells were seeded at a density of 2000-5000 cells/well in 96-well plates, grown overnight. They were subject to various treatments. After 48 or 72 h, MTT was added (50 mg/well) for 4 h. Solubilization of the converted purple formazan dye was accomplished by placing cells in 100 ml of 0.01 N HCl/10% SDS and incubating overnight at 371C. The reaction product was quantified by absorbance at 570 nm. All samples were made in triplicate, and data were analysed by Student's t-test.
In vitro clonogenic assay
After transfection, cells were returned to 371C incubation and maintained for 8 days. Cells were then fixed for 15 min with 3 : 1 methanol : acetic acid and stained for 15 min with 0.5% crystal violet (Sigma) in methanol. After staining, colonies were counted by the naked eye with a cutoff of 50 viable cells. Surviving fraction was calculated as (mean colony counts)/ (cells inoculated) Â (plating efficiency (PE)), where PE was defined as (mean colony counts)/(cells inoculated for unirradiated controls).
Tumor volume assessment
Female athymic nude mice (nu/nu, 5-6 weeks old; Harlan Sprague Dawley Inc., Indianapolis, IN, USA) received subcutaneous injection of one million H460 cells into the right hind limb. After 7-10 days, when average tumor volume reached 0.2 cm 3 , mice were stratified into groups (five mice per group), so that the mean tumor volume in each group was comparable. Treatment groups consisted of: MS oligo alone, AS-survivin alone, AS-XIAP alone, AS-survivin þ AS-XIAP, radiation þ MS, AS-survivin þ radiation, AS-XIAP þ radiaradiation, AS-survivin þ AS-XIAP þ radiation, and control, respectively. The radiation groups received 10 Gy of radiation fractionated over 5 consecutive days (from day 3 to day 7) using a Cobalt irradiator to the tumor with the remainder of the body shielded with lead. The oligo groups received daily intraperitoneal (i.p.) injection (from day 1 to day 7). Tumor volume measurements began on treatment day 1 and continued every 2 days until the tumor volumes became 10% of the body size, approximately 2.5-3 weeks. Measurements were made using skin calipers, as previously described. (Geng et al., 2001; Edwards et al., 2002) Tumor volumes were calculated using a formula (a Â b Â c/2), which was derived from the formula for an ellipsoid. Data were calculated as the percentage of the original (day 1) tumor volume and graphed as percent change in tumor volume7s.d., for each treatment group (Geng et al., 2001; Edwards et al., 2002) . At the same time, the body weight was recorded as a surrogate for systemic toxicity.
Abbreviations HUVEC, human umbilical vein endothelial cells; VEGF, vascular endothelial growth factor; IAP, inhibitor of apoptosis; ASO, antisense oligonucleotides; XIAP, X-linked inhibitor of apoptosis protein.
